The goal of this clinical trial is to assess the efficacy and safety of microblepharoeexfoliation (MBE), intense pulse light (IPL) and meibomian gland expression (MGX) combination in patients with meibomian gland dysfunction (MGD). The main question it aims to answer are: * Does MBE-IPL-MGX treatment improve dry eye symptoms? * Does MBE-IPL-MGX treatment improve dry eye signs? Participants were assigned to receive either three sessions of MBE-IPL-MGX treatment and home-based therapy (treatment group) or home-based therapy alone (control group). The investigators will compare both groups to see if MBE-IPL-MGX treatment is superior to home-based therapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Ocular surface disease index (OSDI) questionnaire.
Timeframe: Change from Baseline OSDI at 2 months.
Tear meniscus height (TMH)
Timeframe: Change from Baseline TMH at 2 months.
Tear meniscus area (TMA)
Timeframe: Change from Baseline TMA at 2 months.
Noninvasive tear film break-up time (NIBUT).
Timeframe: Change from Baseline NIBUT at 2 months.
Lipid Layer Grade (LLG)
Timeframe: Change from Baseline LLG at 2 months.
Ciliary hyperemia
Timeframe: Change from Baseline Ciliary Hyperemia at 2 months.
Conjunctival hyperemia
Timeframe: Change from Baseline Conjunctival Hyperemia at 2 months.
Meibomian glands Loss area (LAMG)
Timeframe: Change from Baseline LAMG at 2 months.
Meibomian gland secretions (MGS)
Timeframe: Change from Baseline MGS at 2 months.
Meibomian gland Dysfunction Grade (MGD Grade)
Timeframe: Change from Baseline MGD grade at 2 months.
Ocular surface staining (OSS).
Timeframe: Change from Baseline OSS at 2 months.